Capecitabine in operable triple receptor–negative breast cancer: A subgroup analysis of a randomized phase III trial.
Kelly C, Green M, Broglio K, Pusztai L, Thomas E, Brewster A, Valero V, Ibrahim N, Gonzalez-Angulo A, Booser D, Hunt K, Hortobagyi G, Buzdar A. Capecitabine in operable triple receptor–negative breast cancer: A subgroup analysis of a randomized phase III trial. Journal Of Clinical Oncology 2011, 29: 292-292. DOI: 10.1200/jco.2011.29.27_suppl.292.Peer-Reviewed Original ResearchTriple-negative breast cancerRelapse-free survivalPathological complete responseOperable triple-negative breast cancerOverall survivalSubgroup analysisBreast cancerWeeks x 4 cyclesRandomized phase III trialReceptor-negative breast cancerTriple receptor-negative breast cancerAddition of capecitabineProportion of patientsTiming of chemotherapyPhase III trialsUnplanned subgroup analysisNegative breast cancerMedian followPreoperative therapyDistant recurrenceIII trialsComplete responsePatientsD1-14Capecitabine